Opus Genetics is trading 5% down at $2.90 following a broad risk-off move in U.S. equities and a sharp decline in the Nasdaq on July 23.
- The stock appears to be moving in line with weaker biotech and growth sentiment, as no company-specific announcements were found to explain the decline.
- Broader market pressure from technology selling, higher interest rates, and geopolitical tensions is weighing heavily on small-cap biotech names.
- Shares are currently trading below the recent $3.05 close, reinforcing the prevailing downside pressure.